Navidea
Navidea researches and develops precision immunodiagnostic agents and immunotherapeutics for the treatment of cancer and cardiovascular diseases.
Business Model:
Revenue: $211.8k
Employees: 2-10
Industries / Tags:
Detailed Navidea Information
Geographic Data
Address: 4995 Bradenton Avenue
City: Dublin
State: OH
Zip: 43017
Country: US
Financial Info
Stage:
post ipo debt
Raised Last:
$1M
Raised Total:$101M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Navidea researches and develops precision immunodiagnostic agents and immunotherapeutics for the treatment of cancer and cardiovascular diseases.
Contact Phone:
+16147937500
Contact Email:
Navidea went public on 11/10/1992 on the NYSE
Listed Exchange:
NYSE
IPO Date:
11/10/1992
Ticker Symbol:
NAVB
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2018 | Private Placement | $3M | 2/2020 | Private Placement | $3.4M | 9/2015 | Grant | $1.8M | 6/2019 | Post-IPO Equity | $6M | 12/2019 | Private Placement | $1.9M | 3/2014 | Post-IPO Debt | 1 | $30M |
Oxford Finance LLC Oxford Finance LLC |
3/2021 | Post-IPO Equity | 1 | $5M |
John K. Scott John K. Scott |
1/2014 | Post-IPO Equity | $2.5M | 7/2022 | Post-IPO Debt | 1 | $1M |
John K. Scott John K. Scott |
4/2022 | Post-IPO Debt | $2.5M | 5/2015 | Post-IPO Debt | 1 | $60M |
CRG CRG |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 12/2001 | Cardiosonix |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
